The GLP-1 Endgame: Value Is Migrating Off the Molecule
Lilly catches Novo, Ypsomed sells diabetes care, Virta cuts GLP-1 use, WeightWatchers files Chapter 11. Where the next decade of obesity-care value sits.
Read More
Oncology's Data Gold Rush: The Asset Is the Patient Data
In 2025 pharma majors moved from buying AI to building it on someone else's data. Tempus and ConcertAI showed the asset in oncology AI is the patient data.
Read More
The AI Adoption Challenge: Go Beyond the Shiny Object in 2026
After a decade of digital transformation consulting and supporting brands through emerging technology adoption, 2025 revealed the hardest truth about AI implementation: technology was never the bottleneck. People and culture were.
How a Venture Partner Drives Fintech Innovation: An Interview with Michele Mattei of Allegory Capital
At Allegory Capital, the venture partner model occupies a central position. Michele Mattei, a fintech professional with a background spanning digital banking, accelerators and angel investing, exemplifies how this hybrid role translates market knowledge into portfolio value.
Read More
How to Lead Investor Meetings Like a Pro: The Structure That Converts Interest into Commitment
The Moment That Separates Pretenders From Performers¹ You’ve rehearsed your pitch deck...
Read More
European Venture Capital Performance Holds Strong—But for How Long?
Europe’s venture capital stays ahead with rising valuations and dry powder, but liquidity challenges threaten its lead as US exits regain pace.
Read More
Switzerland’s Venture Capital Reality Check: A Biotech Mirage in a Hollowed Ecosystem
This article is an analysis of the SECA Venture Capital 2025 Mid-Year...
Read More
Europe’s Startup Support Machine: How Incubators and Accelerators Work?
The European Startup Ecosystem: Growth, Funding, and the Long-Term Dilemma Europe’s startup...
Read More
Raising Venture Capital
Friends or family When you start raising money for your company, one...
Read More